915296-93-4

Upstream product

• 100-46-9 benzylamine 
• 23583-21-3 ethyl-3-benzylamino propionate 
• 915296-86-5 Ethyl 6-benzyl-4-(2,4-dichlorophenyl)-2-methyl-7-oxo-4,5,6,7-tetrahydro-1H-pyrrolo[3,4-b]pyridine-3-carboxylate 
• 1135991-71-7 1-benzoyl-5-benzyl-2-(2,4-dichlorophenyl)-5-azaspiro[2.4]heptane-6,7-dione 
• 915296-87-6 Ethyl 6-benzyl-4-(2,4-dichlorophenyl)-2-methyl-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-3-carboxylate 

Downstream Products

• 1163203-88-0 C₂₂H₁₉Cl₃N₂ 

Relevant academic research and scientific papers

7-Oxopyrrolopyridine-derived DPP4 inhibitors - Mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site

Design, synthesis, and SAR of 7-oxopyrrolopyridine-derived DPP4 inhibitors are described. The preferred stereochemistry of these atropisomeric biaryl analogs has been identified as Sa. Compound (+)-3t, with a Ki against DPP4, DPP8, and DPP9 of 0.37 nM, 2.2, and 5.7 μM, respectively, showed a significant improvement in insulin response after single doses of 3 and 10 μmol/kg in ob/ob mice.

Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods

Compounds are provided having the formula (I) wherein R, X, Y, Z, A and n are as defined herein, which are inhibitors of dipeptidyl peptidase IV and thus are useful in treating diabetes and related diseases.